Basic Information
| LncRNA/CircRNA Name | HULC |
| Synonyms | NA |
| Region | GRCh38_6:8435568-9294133 |
| Ensemble | ENSG00000251164 |
| Refseq | NR_004855 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP |
| Sample | HCC cell lines 97H and LM3, The 7702, HepG2, Huh7, Hep3B and ALEX, HCC tissues compared with controls (adjacent non-tumor liver tissue) |
| Expression Pattern | up-regulated |
| Function Description | HULC is overexpressed in HCC tissues, which correlates with an unfavorable prognosis in HCC patients. We also found that HULC promotes the proliferation, migration, and invasion of HCC cells in vitro, and xenograft tumor growth in vivo. Our mechanistic studies showed that HULC works as a competing endogenous RNA for miR-2052, and that the MET receptor tyrosine kinase is a downstream target of miR-2052 in HCC. Furthermore, HULC inhibits miR-2052, thereby stimulating MET expression in HCC. Finally, MET overexpression reverses the effects of HULC depletion. |
| Pubmed ID | 31645479 |
| Year | 2019 |
| Title | Long noncoding RNA HULC promotes hepatocellular carcinoma progression |
External Links
| Links for HULC | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |